SHANGHAI, Oct. 19, 2015 /PRNewswire/ -- WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), a leading open-access R&D capability
and technology platform company serving the pharmaceutical,
biotechnology and medical device industries, announced today that
Dr. Peter Schultz visited WuXi
AppTec's Shanghai headquarters on
October 17 and gave an inspiring
public lecture. Dr. Schultz is the CEO of The Scripps Research Institute and the founder and
Director of the California Institute for Biomedical Research.
He is also a member of the National Academy of Sciences in
the United States and of its
Institute of Medicine.
Dr. Schultz's research is at the interface of chemistry and
biology. By developing technologies to make and characterize
molecules and materials hundreds to millions at a time, his work
has dramatically impacted our ability to create molecules with
novel biological and physical properties, ranging from medicines to
materials. He has pioneered the development of new drugs that
affect endogenous stem cells for neurodegenerative diseases and
diseases of aging and has led efforts that have resulted in new
therapies for the treatment of multiple sclerosis, lung and blood
cancers, and malaria. Dr. Schultz is a founder of nine
biotech or technology companies that have pioneered the application
of innovative molecular diversity technologies in the fields of
energy, materials science, and human health.
"It is our great honor to host Dr. Schultz's visit to WuXi,"
said Dr. Ge Li, Chairman and CEO of
WuXi AppTec. "His passion for science and his record of
accomplishment are impacting both academia and industry in
significant ways and will continue to inspire our 9,000 scientists
in their pursuit of scientific excellence and innovative solutions
for our partners and patients."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States.
As a research-driven and customer-focused company, WuXi PharmaTech
provides a broad and integrated portfolio of services throughout
the drug and medical device R&D process. WuXi is also
building a platform to provide clinical diagnostic services
directly to physicians and their patients globally. WuXi
PharmaTech's services are designed to assist its global partners in
shortening the cycle and lowering the cost of drug and medical
device R&D. WuXi PharmaTech's operating subsidiaries are
known as WuXi AppTec. For more information, please visit:
http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for
investors)
LaVoieHealthScience
+1-617-374-8800 x109
+1 617-792-2459
ir@wuxiapptec.com
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
pr@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dr-peter-schultz-ceo-of-the-scripps-research-institute-visits-wuxi-apptec-headquarters-in-shanghai-300161745.html
SOURCE WuXi PharmaTech (Cayman) Inc.